MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

NCT06165250 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2025-11-25

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia

Conditions

  • Essential Hypertension
  • Primary Hypercholesterolemia

Interventions

DRUG

BR1018C

One tablet administered alone

DRUG

BR1018C-1

One tablet administered alone

DRUG

BR1018A

One tablet administered alone

DRUG

BR1018A-1

One tablet administered alone

DRUG

BR1018B

One tablet administered alone

DRUG

BR1018B-1

One tablet administered alone

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-17
Primary Completion
2025-11-11
Completion
2025-11-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06165250 on ClinicalTrials.gov